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a  b  s  t  r  a  c  t
Infection after total knee replacement (IATJ) is a rare complication. It is associated with
increased morbidity and mortality increasing the ﬁnal costs. Gram positive coccus and
Staphylococcus coagulase-negative and Staphylococcus aureus are the most common isolated
germs (>50% of the cases). Conditions related to the patient, to the surgical procedure and
even to the post op have been identiﬁed as risk factors to IATJ. Many complementary meth-
ods together with clinical symptoms are useful to a proper diagnosis. Treatment for IATJ
must  be individualized but generally is a combination of systemic antibiotic therapy and
surgical treatment. Prosthesis exchange in one or two stages is the ﬁrst choice procedure.
Debridement with prosthesis retention is an option in acute cases with stable implants and
antibiotic sensible germs.
© 2013 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda.  
Infecc¸ão  em  artroplastia  total  de  joelho:  diagnóstico  e  tratamento
alavras-chave:
ntibacterianos
r  e  s  u  m  o
Infecc¸ão após artroplastia total do joelho (IATJ) é complicac¸ão incomum. Está associada a
aumento da morbimortalidade e dos custos de internac¸ão. Cocos gram-positivos, sobretudo
Este é um artigo Open Access sob a licença de CC BY-NC-NDrtroplastia do joelho
esbridamento
nfecc¸ão
Staphylococcus coagulase-negative e Staphylococcus aureus, são os germes mais comumente iso-
lados (> 50% de todos os casos). Condic¸ões ligadas ao paciente, ao procedimento cirúrgico e
mesmo ao pós-operatório têm sido identiﬁcadas como fatores de risco para IATJ. Vários são
os  métodos complementares que se somam à investigac¸ão clínica para o diagnóstico infec-
cioso e melhor caracterizac¸ão do quadro. O tratamento para a IATJ deve ser individualizado, Study conducted at the Hospital Madre Teresa, Belo Horizonte, MG, Brazil.
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mas  geralmente envolve a combinac¸ão da antibioticoterapia sistêmica com o tratamento
cirúrgico. A troca do implante em um ou dois estágios é o procedimento de escolha. Desbri-
damento com retenc¸ão da prótese é opc¸ão em casos agudos, com implantes estáveis e com
germes sensíveis aos agentes antimicrobianos.
©  2013 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por ElsevierIntroduction
Infection after total knee arthroplasty (TKA) is a topic of great
interest for orthopedists and infectologists. Alternatives for
diminishing the TKA infection rate have long been sought,
given that these rates continue to be between 0.4% and 2%
after primary arthroplasty and between 3.2% and 5.6% after
revision arthroplasty.1–5 Long-term follow-up has shown a
periprosthetic infection rate of 1.55% over the ﬁrst two years
after TKA and 0.46% per year after this period, until the tenth
year.6,7 TKA is a procedure performed worldwide, with 600,000
surgical procedures per year in the USA and a mean survival
rate of 95% over 15 years.8–10 Kurtz et al.10 predicted that there
would be an increase in the demand for TKA of 673% by 2030.
Although the TKA infection rate may seem low, the number
of such injuries tends to increase with increasing numbers of
procedures.
Clinical complications and increased costs associated with
TKA injuries have been of growing concern. The mortality rate
among patients over the age of 65 years who  were awaiting a
surgical procedure for treating TKA infection has ranged from
0.4% to 1.2%, and between 2% and 7% among patients aged
over 80 years.11 The mean cost of treating TKA infections has
been estimated as 50,000 dollars per patient and 250 million
dollars per year, in the United States.12,13
The microorganisms most commonly encountered in
TKA infection cultures are coagulase-negative Staphylococcus
(30–43%) and Staphylococcus aureus (12–23%), followed by con-
tamination due to mixed ﬂora (10%), Streptococcus (9–10%),
Gram-negative bacilli (3–6%) and anaerobic bacilli (2–4%). No
germ is isolated in around 11% of the cases.14,15
This review had the aim of discussing the diagnosis and
treatment of patients with a condition of TKA infection.
Risk  and  prevention  factors
TKA infection has been correlated with a number of risk fac-
tors: diabetes, malnutrition, smoking, use of steroids, poor
control over anticoagulation, obesity, cancer, alcoholism, uri-
nary tract infections, multiple blood transfusions and revision
surgery. The current guidance is that such factors should be
identiﬁed and multidisciplinary intervention should be imple-
mented before performing any procedure, with the aim of
getting the patient into a better condition.16
Use of antimicrobial prophylaxis, care in preparing the
patient’s skin before the operation and use of laminar ﬂow
in surgical theaters have reduced the intraoperative con-
tamination rates. Forty years ago, for every 10 patients who
underwent TKA, one would develop infection.17,18Editora  Ltda.  
Malinzak et al.19 reported that the infection rate was 0.51%
among 8494 hip and knee arthroplasty procedures. They found
that the risk factors for infection were obesity, early age and
diabetes mellitus. Patients with body mass index greater than
40 and those with diabetes presented a 3.3 and 3.1 times
greater chance of TKA infection, respectively. Glycemic con-
trol has been a topic greatly discussed. The beneﬁts of rigorous
control, both before and after the operation, were reported by
Marchant et al.20 and Van den Berghe et al.21
Obesity is a risk factor and is also correlated with wound
complications, as demonstrated by Winiarsky et al.,22 in a
study in which 22% of the obese group of patients presented
infection of the surgical wound and higher prevalence of deep
infection. Obesity is not necessarily synonymous with nutri-
tion, and evaluating transferrin, albumin and leukocytes has
been important in these cases.
Persistence of drainage during the postoperative period
and wound complications are also factors associated with
infection. Galat et al.23 reported that the infection rate was
higher in the group of patients in whom there was hematoma
formation. This was also reported by Parvizi et al.,24 who
indicated that the infection rate was higher in cases with per-
sistent drainage through the surgical wound and in patients
who presented RNI > 1.5.
Clinical  presentation  and  diagnosis
The evaluation and management of patients with TKA infec-
tion should follow a logical, clear and reproducible sequence.
The American Academy of Orthopedic Surgeons (AAOS)
has developed clinical practice guidelines for this process
(Figs. 1–3).
TKA infections can be temporally divided into three types:
acute (less than three months), subacute (three to 24 months)
and chronic (>24 months).25,26 The time period analyzed
relates to the start of the infectious condition and is impor-
tant in determining the treatment. The ﬁrst two  forms of
presentation are linked to the surgical procedure and the
last to bacteremia, generally relating to the skin, teeth or
genitourinary tract.27 Acute infections are characterized by
pain, edema, heat, erythema and fever, commonly caused by
virulent germs such as S. aureus and Gram-negative bacilli.
Patients with subacute conditions (coagulase-negative Staphy-
lococcus and P. acnes) usually have signs and symptoms that are
non-evident and may present persistent pain, implant loos-
ening or both, which makes aseptic loosening a differential
14
Este é um artigo Open Access sob a licença de CC BY-NC-NDdiagnosis. The chronic condition has variable presentation,
with signs and symptoms that are similar to those reported in
the acute and subacute conditions. From the assessment and
the clinical history, it can be deﬁned whether the patient has
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High likelih ood of inf ec on One or  more  symptom s, and  at  least  one  or  mor e:
1) Risk factor  OR
2) Clini cal examinaon OR
3) Ear ly loo sening of  an implant (d etecte d on  radiograph )
Low likelihood of infecon Pain or joint sﬀness and none of the items below:
1) Risk factor OR
2) Clinical examinaon OR
3) Ear ly loo sening of  an implant (d etecte d on  radiograph )
Symptoms Risk factors - literature Risk factors -
consensus
Clinical
examinaon
Others
1- Join t pain
2- Joint  sﬀness
1- Previous  jo int
infecon
2- Superﬁcial infecon
3- Obesity
4- Du raon  of  surger y
> 2.5 h
5- Immunosuppression
1- Recent
bacteremia  (<  1
year)
2- Metach roni c
infecon
3- Sk in disord ers
4- Drugs with
intravenous
acon
5- Acve  infecon
at other  site
6- Recent
inf econ  or
colonizaon  by
Staphylo  MRS A
(< 3 ye ars)
1- Edema ,
reddening
and heat
2- Fi stul a
associated
with surg ical
site
1- Early
loos ening  of
impl ant  (<  5
years),
detect ed on
radiogra ph
Fig. 1 – Stratiﬁcation of the risk factors.
Reproduced with modiﬁcations from “The diagnosis of periprosthetic joint infections of the hip and knee. Guideline and
evidence report”. Adopted by the American Academy of Orthopedic Surgeons Board of Directors, June 18, 2010. American
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igh or low likelihood of infection, which is important for the
ubsequent propaedeutics.
After clinical and temporal characterization, laboratory
ests form part of the investigation of infections. C-reactive
Patient  with  high likelihood  of  PTJI
PCR/VHS positive? Join t aspira tio n
Cell
count/ diff eren tia
positive or  cul tu 
positive?
Yes
Either cell
count/ diff eren 
positive or  cu 
positive?
Infec tion  un likely
No
No
Fig. 2 – Algorithm for managing patients with a
Reproduced with modiﬁcations from “The diagnosis of peripro
evidence report”. American Academy of Orthopedic S;18(12):760–770 (with permission).
protein (CRP) levels and erythrocyte sedimentation rate (ESR)
are evaluated in patients with suspected TKA infection.
Carvalho Junior et al.28 demonstrated that CRP and ESR return
to levels lower than the preoperative levels in 30 and 80
l
re
Infe ction  def ined
tial
ltur e
Yes
Yes Repeat aspira tion :
Positive?
Surge ry planned ?
Scin tigraph y
positive?
Infe ctio on def inedYes
No
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No
Frozen  section  or
periopera tive cel l
analysis po sitive?Yes
Yes
No
 high likelihood of infection following TKA.
sthetic joint infections of the hip and knee. Guideline and
urgeons, 2010;18(12):760–770 (with permission).
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Fig. 3 – Algorithm for managing patients with a low likelihood of infection following TKA.
ipro
dic SReproduced with modiﬁcations from “The diagnosis of per
evidence report”. American Academy of Orthope
days, respectively, after non-complicated TKA. Piper et al.29
reported that the cutoff values for CRP and ESR were 14.5 mg/L
and 19 mm/h, respectively, for diagnosing TKA infection.
Another important laboratory tool for the diagnosis has been
interleukin 6 (IL-6). A recent meta-analysis showed that the
diagnostic accuracy was best using IL-6 values, followed by
CRP, ESR and leukocyte counts.30 Other markers (alpha-1 gly-
coprotein acid and procalcitonin) have emerged, although still
without applicability within clinical practice.
Imaging examinations can also be used to complement the
evaluation, but are not essential for diagnosing the infection,
nor do they rule it out. Simple anteroposterior and lateral
radiographs are useful when evaluated comparatively with
previous images.31 Periosteal reactions, component migra-
tion and osteolysis are signs of possible involvement of
infection. Bone scintigraphy, computed tomography, magnetic
resonance imaging and PET scans may also be used, while
respecting their indications and objectives. Scintigraphy using
technetium-99m has high sensitivity but little speciﬁcity for
infection, and may give false positive results for up to one year
after the primary procedure, because of bone remodeling.32
Using leukocytes marked with indium-111, accuracy of 81%
has been achieved in diagnosing TKA infection.33 The AAOS
has recommended that triphasic bone scintigraphy should be
used in cases with a high likelihood of TKA infection following
negative cultures. Tomography allows better contrast between
normal and infected tissues, but the presence of artifacts
caused by metal limits its use. With technical modiﬁcations,
magnetic resonance imaging may be useful for making the
diagnosis, particularly in cases involving the femoral implant.
PET scans have shown accuracy of 77.8% in diagnosing infec-
tion, with sensitivity of 90% and speciﬁcity of 89.3%.34–36 In
the investigative process, aspiration of synovial ﬂuid from the
joint is important. It should be analyzed in the laboratory tosthetic joint infections of the hip and knee. Guideline and
urgeons, 2010;18(12):760–770 (with permission).
quantify the total leukocyte count and the percent of polymor-
phonuclear leukocytes. Counts greater than 3000 leukocytes
per microliter with neutrophils counts of at least 60% are
considered to be the criteria for diagnosing subacute or
chronic infection. Culturing the aspirate has the objective of
identifying the germ and establishing its sensitivity pattern.
Use of Gram has not been indicated because of its low sensi-
tivity and speciﬁcity.37–39 Parvizi et al.40 demonstrated that the
colorimetric test for detecting leukocyte esterase in the syno-
vial ﬂuid is highly sensitive and speciﬁc for diagnosing TKA
infection and also has the beneﬁts of providing a result in two
minutes and having low cost.
For acute cases, counts of more  than 27,800 leukocytes per
microliter have presented positive predictive value of 94%,
while other markers have not been shown to be useful because
of the normal inﬂammatory response of the immediate post-
operative period.41
The culturing should be done for aerobic germs, anaerobic
germs and fungi, which sufﬁcient time allowed for observing
the growth of all of these. Cultures on ﬁstulous passages or
swabs do not have any value.
During the surgery, at least three samples should be col-
lected from different locations and preferably after stopping
the use of antibiotics. Studies have shown sensitivity of
60% with classical laboratory culturing techniques. Sonica-
tion techniques have increased the sensitivity to 83.3%.25,42
In cases of negative cultures before or during the operation,
histological analysis can be performed, with perioperative
frozen-section biopsy or repetition of joint puncture after an
interval of six weeks.If the likelihood of TKA infection is low, and provided
that all the evaluations are negative, observation for three
months is recommended, with reassessment at the end of this
period.
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Combining the clinical history, laboratory alterations and
ulture results guides and enables identiﬁcation of the infec-
ious condition. In around 5–10% of the cases, alterations may
xist throughout the propaedeutics, but without conﬁrmation
rom culturing. Berbari et al.43 reported that it was important
hat the treatment should be guided in accordance with the
ntire investigation, and not just the results from culturing.
n evaluating 897 cases of periprosthetic infection, they found
hat 7% of the cases had false negative cultures. All of these
ases underwent surgical or drug treatment with a ﬁve-year
uccess rate of greater than 70%.
reatment
he primary objective in treating TKA infection is to eradi-
ate the infection. Pain relief and reestablishment of function
re secondary objectives, but no less important. Through the
nﬂuence of the American literature, debridement with reten-
ion (D + R) and replacement in a single procedure (1T) are
sed less frequently. In addition, temporary placement of a
pacer containing antibiotics, followed by replacement with
he deﬁnitive implant (2T)44–46 and suppression therapy (ST),
as also been proposed. Segawa et al. deﬁned four clinical
hases of TKA infection that are useful for guiding the treat-
ent: I – infection identiﬁed at the time of the procedure; II
 acute postoperative infection; III – identiﬁcation some years
fter the original procedure, coming from a distant focus; IV –
hronic infection.
The surgical treatments that exist in cases of infectious
onditions are D + R, 1T, 2T, resection arthroplasty, arthrodesis,
mputation and ST.44 The choice of best treatment depends on
he patient’s condition, the condition of the implant and the
erm that was isolated.
D + R is a good alternative for patients with early postop-
rative infectious states and acute hematogenic conditions,r subacute prosthetic infection.
provided that the duration of symptoms is no more  than three
weeks, the skin coverage conditions are adequate, the implant
is stable and an antimicrobial agent with effective action
is available. It has been recommended that initial venous
antibiotic therapy should be used for two to four weeks, with
conversion to oral medication after this period.46,47 Byren
et al.48 demonstrated that the infection-free survival rate after
D + R treatment was 82%, with a follow-up of 2.3 years. Fail-
ure was associated with arthroscopic treatment, infections
in revision procedures and infection due to S. aureus.  Trebse
et al.49 applied a D + R protocol to a series of 24 patients with
an 86% success rate over three years and deﬁned that the fac-
tors for a good prognosis were the presence of a stable implant,
absence of ﬁstulas contiguous with the prosthetic component
and duration of symptoms less than three weeks.
Replacement in a single procedure is a good option when
there is good skin coverage, absence of comorbidities and
infection not caused by multiresistant germs. Jämsen et al.50
reported that the infection eradication rates ranged from 73%
to 100% over 122 months of follow-up using this strategy.
If these criteria are not all fulﬁlled, the best option is to
replace the implant in two procedures (2T). In these cases, a
mobile or rigid joint spacer made of polymethylmethacrylate
(PMM) should be used. This has the objectives of keeping the
soft tissues under tension, diminishing the “dead space” and
enabling local release of antibiotic.51,52 In these cases, Zim-
merli et al.46 recommended that the second procedure should
be performed after as short a time as possible (two to four
weeks), which diminishes the costs and the duration of hospi-
tal stay. Haleem et al.51 reported that the success rate over ﬁve
years of follow-up was 93.5% and over 10 years, 85%. Macheras
et al.52 reported that the infection-free survival rate was 91.1%
over 12.1 years of follow-up.
Despite concerns among infectologists that spacers with
low release of antibiotics (which occurs after a few weeks of
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Intact or  minimall y
compromised
Compromis ed
Abscess or  fistul a
Agents that are
diff icult to trea t
MRSA, GNB,  MR
Entero coccus
Fung i
Sing le-stag e
exchang e
Drainage  prolonge d
antib iotic
Patien t’s ge neral  condi tio n
or surgi cal risk
Debilitated , bed ridden  an d
not in a cond ition fo r
other  surge ry
Comorbidites
Immunodepre ssed
Without  functiona l
improvemen t
(withou t mob ility)
Two-stage  exchang e
Long interval  (6  to  8
weeks)
Drainage  with spa cer
Prolonged  an tib iotic
Suppres sio n
treat ment  wit h
antib iotic  for
prolonged  perio d
Removal  of
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situa tion s
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Removal of  prosth esis
Fig. 5 – Algorithm for treating infection that is not qualiﬁed for debridement + retention.use) might function as sites for bacterial ﬁxation (through for-
mation of bioﬁlm), there is no consensus regarding the ideal
length of time for the spacer to be kept in use. Della Valle53
suggested that the minimum time should be eight weeks, pro-
vided that after the end of the initial antibiotic therapy (six
weeks), the values from inﬂammatory tests continue to show
progressive reductions over the subsequent two weeks.
Another point that is still under discussion is the mixture
of antibiotics with the PMM  and its concentration. There is
no standardization of the quantity used. Empirically, 10% of
its weight has been used, which represents 4 g of antibiotic
for each unit (40 g). It is known that high doses of antibi-
otic may alter the mechanical properties of the spacer and
make it easily breakable.54 Despite this, Anagnostakos et al.55
reported that they used high doses of antibiotics in PMM,
without major clinical repercussions or side effects. Although
manufactured formulations of PMM  in association with gen-
tamicin and tobramycin exist, the dosage of these antibiotics
in the mixture does not reach the 10% mentioned above. When
the antibiotic is mixed in on the surgical table, it is possible
to add the antibiotic to the most external layer of the PMM
and increase its area of contact with the bone surface (place-
ment as a surface coating). The choice of antimicrobial agent
depends on the germ to be treated and the thermoresistance
of the agent, given that the polymerization reaction of the
PMM when associated with barium is exothermic and may
interfere with the properties of the antibiotic. Gentamicin,
tobramycin and vancomycin are good alternatives as ther-
moresistant agents.56,57In addition to surgical treatment, systemic antibiotic
therapy should be maintained. It has been recommended
that there should be six months of treatment for patients
with TKA infection who present unfavorable skin coverage
conditions.45,46 The antimicrobial agent should have bacte-
ricidal action, even against slow-growth germs or bioﬁlm
producers. Before starting any treatment, the susceptibility of
the germ should be tested and alternative regimens should be
discussed, given the growing levels of resistance.57,58 A com-
bination of rifampicin with quinolones has been used most
often, with good results in vitro, in vivo and in clinical trials.
Options such as linezolid, sulfamethoxazole-trimethoprim
and minocycline are possible, although so far no clinical stud-
ies for validating their use have been published. The best
option is to discuss the best antimicrobial therapy for each
case with the hospital infection control committee.58,59
If the patient is not in a suitable clinical condition for the
new procedure, ST with long-duration antimicrobial medica-
tion becomes the best option. In these cases, the objective
becomes one of controlling the acute manifestations, rather
than eradication of the infection. Arthrodesis and amputa-
tion are options for immunocompromised patients and for
those for whom new arthroplasty would not improve their
function.59
Using the AAOS and Zimmerli recommendations described
in Figs. 4 and 5, Giulieri et al.60 reported that the cure rate
was 83%, while Trampuz et al.,61 Tsukayama et al.,62 Meehan
et al.63 and Betsch et al.64 observed cure rates of 90%, 91%, 89%
and 57%, respectively. Betsch et al.64 found values lower than
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3r e v b r a s o r t o p . 2
hose of the others because they had a greater number of 2T
rocedures, with a greater number of cases of advances dis-
ase or microorganisms of greater virulence. The risk factors
or therapeutic failure were described as polymicrobial infec-
ion and infection due to Gram-negative bacilli, mycobacteria
nd fungi.
With better comprehension of the pathogenesis of the
isease and development of new diagnostic and investiga-
ive techniques, better treatment and management of TKA
nfection will be achieved, with fewer complications and
orbidity–mortality.
inal  remarks
fter TKA infection has been diagnosed, its treatment should
e individualized but generally involves a combination of sys-
emic antibiotic therapy with surgical treatment. Replacement
f the implant in one or two stages is the preferred procedure.
ebridement with retention of the prosthesis is an option in
cute cases that have stable implants and present germs that
re sensitive to the antimicrobial agents.
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